Abstract
Purpose
Pituitary tumors are the second most common intracranial tumors, however, pituitary carcinoma is a rare clinical entity which represents only 0.1–0.2% of all pituitary tumors. Diagnosis of pituitary carcinoma requires the presence of metastasis. Early identification of pituitary carcinoma is difficult, and only recently have guidelines been published for the treatment of aggressive pituitary tumors. We present two cases from our institution, with a review of other cases available in literature in order to better characterize this rare disease.
Methods
A retrospective review of two patients with pituitary carcinoma treated at a tertiary medical center was performed. The MEDLINE database was searched for all cases of pituitary carcinoma. Information for age at diagnosis, sex, pituitary tumor type, latency period from pituitary tumor to presentation of carcinoma, sites of metastasis, number of surgical therapies, radiation and chemotherapy, and survival after diagnosis were collected.
Results
A total of 69 studies were available for review for a total of 72 unique cases. The average age at diagnosis was 46.3 years. The most common tumors were ACTH-secreting (34.7%), Prolactin-secreting (23.6%), and Null Cell (15.3%). The average latency period from pituitary tumor diagnosis to metastasis was 9 years. All patients underwent surgical therapy during their treatment, with an average of 2.76 procedures. The mortality rate was 54.8% with average time to death after diagnosis of approximately 10 months.
Conclusions
Pituitary carcinoma is a rare disease with high mortality rate and is a diagnostic and treatment challenge. Further study is required but is difficult due to its low incidence.
Similar content being viewed by others
References
Heaney AP (2011) Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 96(12):3649–3660
Heaney A (2014) Management of aggressive pituitary adenomas and pituitary carcinomas. J Neurooncol 117:459–468
Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90(5):3089–3099
Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF Jr., Lloyd RV (2005) Pituitary carcinoma: a clinicopathological review. Neurosurgery 56:1066–1074
Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134:521–535
Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28:228–243
Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16(4):E7
Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF, Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79(4):804–812
Hansen TM, Batra S, Lim M, Gallia GL, Burger PC, Salvatori R, Wand G, Quinones-Hinojosa A, Kleinberg L, Redmond KJ (2014) Invasive adenoma and pituitary carcinoma: a SEER database analysis. Neurosurg Rev 37, 279–286
Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM (2017) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumors and carcinomas. Eur J Endocrinol 178(1):G1–24
Sakamoto T, Itoh Y, Fushimi S, Kowada M, Saito M (1990) Primary pituitary carcinoma with spinal cord metastasis—case report. Neurol Med Chir (Tokyo) 30(10):763–767
Atienza DM, Vigersky RJ, Lack EE, Carriaga M, Rusnock EJ, Tsou E, Cerrone F, Kattah JG, Sausville EA (1991) Prolactin-producing pituitary carcinoma with pulmonary metastasis. Cancer 68(7):1605–1610
Tonner D, Belding P, Moore SA, Schhlechte JA (1992) Intracranial dissemination of an ACTH secreting pituitary neoplasm—a case report and review of the literature. J Endocrinol Invest 15(5):387–391
Stewart PM, Carey MP, Graham CT, Wright AD, London DR (1992) Growth hormone secreting pituitary carcinoma: a case report and literature review. Clin Endocrinol (Oxf) 37(2):189–194
Petterson T, MacFarlane IA, MacKenzie JM, Shaw MD (1992) Prolactin secreting pituitary carcinoma. J Neurol Neurosurg Psych 55(12):1205–1206
Yamashita S, Izumi M, Nagataki S (1992) Acromegaly and pituitary carcinoma. Ann Intern Med 117(12):1057–1058
Mixson AJ, Friedman TC, Katz DA, Feuerstein IM, Taubenberger JK, Colandrea JA, Doppman JL, Oldfield EH, Weintraub BD (1993) Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab 76(2):529–533
Cusimano MD, Ohori P, Martinez AJ, Jungreis C, Wright DC (1994) Pituitary carcinoma. Skull Base Surg 4(1):46–51
Beauchesne P, Trouillas J, Barral F, Brunon J (1995) Gonadotropic pituitary carcinoma: case report. Neurosurgery 37(4):810–815
Dayan C, Guilding T, Hearing S, Thomas P, Nelson R, Moss T, Bradshaw J, Levy A, Lightman S (1996) Biochemical cure of recurrent acromegaly by resection of cervical spinal canal metastasis. Clin Endocrinol (Oxf) 44(5):597–602
Lormeau B, Miossec P, Sibony M, Valensi P, Attali JR (1997) Adrenocorticotropin-producing pituitary carcinoma with liver metastasis. J Endocrinol Invest 20(4):230–236
Garrao AF, Sobrinho LG, Pedro-Oliviera, Bugalho MJ, Boavida JM, Raposo JF, Loureiro M, Limbert E, Costa I, Antunes JL (1997) ACTH-producing carcinoma of the pituitary with haematogenic metastasis. Eur J Endorcrinol 137(2):176–180
Kemink SA, Wesseling P, Pieters GF, Verhofstad AA, Hermus AR, Smals AG (1999) Progression of a Nelson’s adenoma to pituitary carcinoma: a case report and review of the literature. J Endocrinol Invest 22(1):70–75
Masuda T, Akasaka Y, Ishikawa Y, Ishii T, Isshiki I, Imafuku T, Ogihara T, Miyazaki H, Asuwa N (1999) An ACTH-producing pituitary carcinoma developing Cushing’s disease. Pathol Res Pract 195(3):183–187
McCutcheon IE, Pieper DR, Fuller GN, Benjamin RS, Friend KE, Gagel RF (2000) Pituitary carcinoma containing gonadotropins: treatment by radical excision and cytotoxic chemotherapy: case report. Neurosurgery 46(5):1233–1239
Zahedi A, Booth Gl, Smyth HS, Farrell WE, Clayton RN, Asa SL, Ezzat S (2001) Distinct clonal composition of primary and metastatic adrenocorticotrophic hormone-producing pituitary carcinoma. Clin Endocrinol (Oxf) 55(4):549–556
Le Roux CW, Mulla A, Meeran K (2001) Pituitary carcinoma as a cause of acromegaly. N Engl J Med 345(22):1645–1646
Sironi M, Cenacchi G, Cozzi L, Tonnarelli G, Iacobellis M, Trere D, Assi A (2002) Progression on metastatic neuroendocrine carcinoma from a recurrent prolactinoma: a case report. J Clin Pathol 55(2):148–151
Pichard C, Gerber S, Laloi M, Kujas M, Clemenceau S, Ponvert D, Bruckert E, Turpin G (2002) Pituitary carcinoma: report of an exceptional case and review of the literature. J Endorcrinol Invest 25(1):65–72
Suzuki K, Morii K, Nakamura J, Kaneko S, Ukisu J, Hanyu O, Nakagawa O, Aizawa Y (2002) Adrenocorticotropin-producing pituitary carcinoma with metastasis to the liver in a patient with Cushing’s disease. Endocr J 49(2):153–158
Landman RE, Horwith M, Peterson RE, Khandji AG, Wardlaw SL (2002) Long-term survival with ACTH-secreting carcinoma of the pituitary: a case report and review of the literature. J Clin Endocrinol Metab 87(7):3084–3089
Roncaroli F, Nose V, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr., Lloyd RV, Bishop MC, Hsi B, Fletcher JA (2003) Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of 2 cases. J Neurosurg 99(2):402–408
Tysome J, Gnanalingham KK, Chopra I, Mendoza N (2004) Intradural metastatic spinal cord compression from ACTH-secreting pituitary carcinoma. Acta Neurochir (Wien) 146(11):1251–1254
Ayuk J, Natarajan G, Geh JI, Mitchell RD, Gittoes NJ (2005) Pituitary carcinoma with a single metastasis causing cervical spinal cord compression. Case report. J Neurosurg Spine 2(3):349–353
Yamashita H, Nakagawa K, Tago M, Nakamura N, Shiraishi K, Yamauchi N, Ohtomo K (2005) Pathological changes after radiotherapy for primary pituitary carcinoma: a case report. J Neurooncol 75(2):209–214
Brown RL, Muzzafar T, Wollman R, Weiss RE (2006) A pituitary carcinoma secreting TSH and prolactin: a non-secretory adenoma gone awry. Eur J Endocrinol 154(5):639–643
Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7(6):518–520
Sivan M, Nandi D, Cudlip S (2006) Intramedullary spinal metastasis (ISCM) from pituitary carcinoma. J Neurooncol 80(1):19–20
Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE (2006) Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105(4):621–626
Tena-Suck ML, Salinas-Lara C, Sanchez-Garcia A, Rembao-Bojorquez D, Ortiz-Plata A (2006) Late development of intraventricular papillary pituitary carcinoma after irradiation of prolactinoma. Surg Neurol 66(5):527–533
Koyama J, Ikeda K, Shose Y, Kimura M, Obora Y, Kohmura E (2007) Long-term survival with non-functioning pituitary carcinoma—case report. Neurol Med Chir (Tokyo) 47(10):475–478
Choi G, Choi HJ, Kim YM, Choi SH, Cho YC, Kim Y, Suh JH, Cha HJ (2007) Pituitary carcinoma with mandibular metastasis: a case report. J Korean Med Sci 22(Suppl):145–148
Koh KP, Lee HY, Rajasoorya RC (2008) Triple jeopardy in the pituitary. Pituitary 11(3):331–336
Scheithauer BW, Kovacs K, Nose V, Lombardero M, Osamura YR, Lloyd RV, Horvath E, Pagenstecher A, Bohl JE, Tews DS (2009) Multiple endocrine neoplasia type 1-associated thyrotropin producing pituitary carcinoma: report of a probable de novo example. Hum Pathol 40(2):270–278
Figueiredo EG, Palva WS, Teixeira MJ (2009) Extremely late development of pituitary carcinoma after surgery and radiotherapy. J Neurooncol 92(2):219–222
Guzel A, Tatti M, Senturk S, Guzel E, Cayli SR, Sav A (2008) Pituitary carcinoma presenting with multiple metastases: case report. J Child Neurol 23(12):1467–1471
Pinchot SN, Sipple R, Chen H (2008) ACTH-producing carcinoma of the pituitary with refractory Cushing’s Disease and hepatic metastases: a case report and review of literature. World J Surg Oncol 7:39
Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161(4):631–637
Ilkhchoui Y, Appelbaum DE, Pu Y (2010) FDG-PET/CT findings of a metastatic pituitary tumor. Cancer Imaging 10:114–116
Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, Thome C (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes 118(10):760–763
Yakoushina TV, Lavi E, Hoda RS (2010) Pituitary carcinoma diagnosed on fine needle aspiration: report of a case and review of pathogenesis. Cytojournal 7:14
Curto L, Torre ML, Ferrau F, Pitini V, Altavilla G, Granata F, Longo M, Hofland LJ, Trimarchi F, Cannavo S (2010) Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing’s disease-report of a case and literature review. Sci World J 10:2132–2138
Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, Ishida Y, Takano K, Okinaga H, Matsuno A (2011) A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. Neurosurgery 68(6):E1761–E1767
Dudziak K, Honegger J, Bornemann A, Horger M, Mussig K (2011) Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course-case report and review of the literature. J Clin Endocrinol Metab 96(9):2665–2669
Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K (2011) Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy. Hormomes (Athens) 10(2):162–167
Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirollos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M (2012) Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. Pituitary 15(3):276–287
Lee W, Cheung AS, Freilich R (2012) TSH secreting pituitary carcinoma with intrathecal drop metastases. Clin Endocrinol (Oxf) 76(4):604–606
Shastri BR, Nanda A, Fowler M, Levine SN (2013) Adrenocorticotropic hormone-producing pituitary carcinoma with intracranial metastasis. World Neurosurg 79(2):404
Arnold PM, Ratnasingam D, O’Neil MF, Johnson PL (2012) Pituitary carcinoma recurrent to the lumbar intradural extramedullary space: case report. J Spinal Cord Med 35(2):118–121
Zhou Q, Chang H, Gao Y, Cui L (2013) Tumor-to-tumor metastasis from pituitary carcinoma to radiation-induced meningioma. Neuropathology 33(2):209–212
Sreenan S, Sengupta E, Tormey W, Landau R (2012) Metastatic pituitary carcinoma in a patient with acromegaly: a case report. J Med Case Rep 6:322
Morokuma H, Ando T, Hayashida T, Horie I, Inoshita N, Murata F, Ueki I, Nakamura K, Imaizumi M, Usa T, Kawakami A (2012) A case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment. Case Rep Endocrinol. https://doi.org/10.1155/2012/645914
Kovacs GL, Goth M, Rotondo F, Scheithauer BW, Carlsen E, Saadia A, Hubina E, Kovacs L, Szabolcs I, Nagy P, Czirjak S, Hanzely Z, Kovacs K, Horvath E, Korbonits M (2013) ACTH-secreting Crooke cell carcinoma of the pituitary. Eur J Clin Invest 43(1):20–26
Zemmoura I, Wierinckx A, Vasiljevic A, Jan M, Trouillas J, Francois P (2013) Aggressive and malignant prolactin pituitary tumors: pathological diagnosis and patient management. Pituitary 16(4):515–522
Phillips J, East HE, French SE, Melcescu E, Hamilton RD, Nicholas WC, Kratkin JF, Parent AD, Luzardo G, Koch CA (2012) What causes a prolactinoma to be aggressive or to become a pituitary carcinoma?. Hormones (Athens) 11(4):477–482
Miller BA, Tanaka T, Ioachimescu AG, Vincentelli C, Appin CL, Oyesiku NM (2013) Transformation of a silent adrenocorticotrophic pituitary tumor into central nervous system melanoma. J Investig Med High Impact Case Rep. https://doi.org/10.1177/2324709613494008
Balili I, Sullivan S, Mckeever P, Barkan A (2014) Pituitary carcinoma with endolymphatic sac metastasis. Pituitary 17(3):210–213
Lall RR, Shafizadeh SF, Lee KH, Mao Q, Mehta M, Raizer J, Bendok BR, Chandler JP (2013) Orbital metastasis of pituitary growth hormone secreting carcinoma causing lateral gaze palsy. Surg Neurol Int 4:59
Park KS, Hwang JH, Hwang SK, Kim S, Park SH (2014) Pituitary carcinoma with fourth ventricle metastasis: treatment by excision and Gamma-knife radiosurgery. Pituitary 17(6):514–518
Maclean J, Aldridge M, Bomanji J, Short S, Fersht N (2014) Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation. Pituitary 17(6):530–538
Cornell RF, Kelly DF, Bordo G, Carroll TB, Duong HT, Kim J, Takasumi Y, Thomas JP, Wong YL, Findling JW (2013) Chemotherapy induced regression of an adrenocorticotropin-secreting pituitary carcinoma accompanied by secondary adrenal insufficiency. Case Rep Endocrinol. https://doi.org/10.1155/2013/675298
Lee HH, Hung SH, Tseng TM, Lin YH, Cheng JC (2014) Undifferentiated carcinoma of the pituitary gland: a case report and review of the literature. Oncol Lett 7(3):778–780
Lin GC, Adams ME, Arts HA (2014) Lesions of the petrous ridge: metastatic pituitary carcinoma with discussion of differential diagnosis. Otol Neurotol 35(4):645–648
Mendola M, Passeri E, Ambrosi B, Corbetta S (2014) Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma. J Clin Endocrinol Metab 99(8):2623–2624
Novruzov F, Aliyev JA, Jaunmuktane Z, Bomanji JB, Kayani I (2015) The use of (68)Ga DOTATATE PET/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma. Clin Nucl Med 40(1):47–49
Takeuchi K, Hagiwara Y, Kanaya K, Wada K, Shiba M, Kato Y (2014) Drop metastasis of adrenocorticotropic hormone-producing pituitary carcinoma to the cauda equina. Asian Spine J 8(5):680–683
Borba CG, Batista RL, Musolino NR, Machado VC, Alcantara AE, da Silva GO, Cescato S, da Cunha VA, Neto MB (2015) Progression of an invasive ACTH pituitary macroadenoma with Cushing’s disease to pituitary carcinoma. Case Rep Oncol Med. https://doi.org/10.1155/2015/810367
Wang YQ, Fan T, Zhao XG, Liang C, Qi XL, Li JY (2015) Pituitary carcinoma with intraspinal metastasis: report of two cases and review of literature. Int J Clin Exp Pathol 8(8):9712–9717
Greenman Y, Woolf P, Coniglio J, O’Mara R, Pei L, Said JW, Melmed S (1996) Remission of acromegaly caused by pituitary carcinoma after surgical excision of growth hormone-secreting metastasis detected by 111-Indium pentetreotide scan. J Clin Endocrinol Metab 81(4):1628–1633
Liu JK, Patel J, Eloy JA (2015) The role of temozolomide in the treatment of aggressive pituitary tumors. J Clin Neurosci 22(6):923–929
Bengtsson D, Schroder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, Rasmussen AK, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolamide. J Clin Endocrinol Metab 100(4):1689–1698
George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr., Lloyd RV, Meyer FB (2003) Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27(10):1330–1336
Cooper O (2015) Silent corticotroph adenomas. Pituitary 18:225–231
Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S, Blevins L, Aghi MK (2013) A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73:8–17
Webb KM, Laurent JJ, Okonkwo DO, Lopes MB, Vance ML, Laws ER Jr. (2003) Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery 53:1076–1084
Xu Z, Ellis S, Lee CC, Starke RM, Schlesinger D, Vance ML, Lopes MB, Sheehan J (2014) Silent corticotroph adenomas after stereotactic radiosurgery: a case-control study. Int J Radiat Oncol Biol Phys 90:903–910
Veit JA, Boehm B, Luster M, Scheuerle A, Rotter N, Rettinger G, Scheithauer M (2013) Detection of paranasal ectopic adrenocorticotropic hormone-secreting pituitary adenoma by Ga-68-DOTANOC positron-emission tomography-computed tomography. Laryngoscope 123:1132–1135
Lopes MB, Scheithauer BW, Schiff D (2005) Pituitary carcinoma: diagnosis and treatment. Endocrine 28(1):115–121
Campdera M, Palacios N, Aller J, Magallon R, Martin P, Saucedo G, Lilienfeld H, Estrada J (2016) Temozolomide for aggressive ACTH tumors: failure of a second course of treatment. Pituitary 19(2):158–166
Losa M, Bogazzi F, Cannavo S, Ceccato F, Curto L, De Marinis L, Iacovazzo D, Lombardi G, Mantovani G, Mazza E, Minniti G, Nizzoli M, Reni M, Scaroni C (2016) Temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas. J Neurooncol 126(3):519–525
Bruno OD, Juarez-Allen L, Christiansen SB, Manavela M, Danilowicz K, Vigovich C, Gomez RM (2015) Temozolomide therapy for aggressive pituitary tumors: results in a small series of patients from Argentina. Int J Endocrinol. https://doi.org/10.1155/2015/587893
Whitelaw BC, Dworakowska D, Thomas NW, Barazi S, Riordan-Eva P, King AP, Hampton T, Landau DB, Lipscomb D, Buchanan CR, Gilbert JA, Aylwin SJ (2012) Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) 76(6):877–886
Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA Jr., Vance ML, Thorner MO, Laws ER Jr., Lopes MB (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280–E290
Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592–4599
Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M (2010) Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163(6):843–861
Ceccato F, Lombardi G, Manara R, Emanuelli E, Denaro L, Milanese L, Gardiman MP, Bertorelle R, Scanarini M, D’Avella D, Occhi G, Boscaro M, Zagonel V, Scaroni C (2015) Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. J Neurooncol 122(1):189–196
Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for hypothalamic and pituitary tumors. J Clin Endocrinol Metab 98(3):1130–1136
Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M, Bonnet F, Bourciqaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assie G, Raverot G (2017) Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol 176(6):769–777
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
There are no financial disclosures or conflict of interest for any authors.
Rights and permissions
About this article
Cite this article
Yoo, F., Kuan, E.C., Heaney, A.P. et al. Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. Pituitary 21, 290–301 (2018). https://doi.org/10.1007/s11102-018-0872-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-018-0872-8